



BC Centre for Disease Control
Provincial Health Services Authority

Communicable Diseases and Immunization Service
655 West 12th Avenue
Vancouver, BC V5Z 4R4

Tel 604.707.2548
Fax 604.707.2515
www.bccdc.ca

Date: August 21, 2020

Administrative Circular: 2020:15

ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization, Introduction, Part 2 – Immunization of Special Populations, Part 4 – Biological Products, and Supporting Documents

Introduction

Guidance for Influenza Vaccine Delivery in the Presence of COVID-19

- A new section has been added to the immunization manual providing guidance to immunization providers on the delivery of seasonal influenza vaccine and mass immunization clinics during the COVID-19 pandemic. The section can also be accessed from the BCCDC website on the Public Health Management page for COVID-19 Care under “Related Links”.

Please add new page numbers: 1-10 dated August 21, 2020

Part 2 – Immunization of Special Populations

Specific Immunocompromising Conditions

Human Immunodeficiency Virus (HIV) Infection

- The recommendations for influenza vaccine have been revised to indicate that the live attenuated influenza vaccine may be considered for those 2-17 years of age and that the referral form for live attenuated influenza vaccination be used.

Please remove page numbers: 1 & 2 dated October 2018

Please add page numbers: 1 & 2 dated August 2020

Page 1 of 4

Referral Forms

Referral Form for Live Attenuated Influenza Vaccination

- The referral form has been revised to include pediatric clients 2-17 years of age with HIV infection.

Please remove page number: 1 dated August 2018

Please add page number: 1 dated August 2020

Part 4 – Biological Products

Hib Vaccines

Haemophilus b Conjugate Vaccine

- Latex has been removed from the product components and contraindications for Act-HIB®.
- Adverse events have been revised to include diarrhea and vomiting based on the product monographs.

Please remove page numbers: 1-2 dated August 2016

Please add page numbers: 1-2 dated August 2020

Influenza Vaccines

2020/21 Seasonal Influenza Vaccines

- Influenza pages for the 2020/21 season have been revised. The eligibility criteria for publicly funded influenza vaccine are unchanged. BC is purchasing higher quantities of influenza vaccines for the 2020/21 season to accommodate additional demand from within the eligible groups due to the COVID-19 pandemic and in response to planned increased promotion of influenza vaccination this season.
- Revisions to the influenza pages include:
 - The vaccine strains contained in the 2020/21 influenza vaccines.
 - The “Intended Use of Influenza Vaccines” table has been revised to include the vaccines for the 2020/21 publicly funded program. The page has a link to the updated Question & Answer Document related to FLUZONE HIGH-DOSE® is also included.
 - New product pages have been added for the 2020/21 influenza season – see below.
 - Quadrivalent Live Attenuated Influenza Vaccine (LAIV-Q): A 4 week interval is no longer recommended between receipt of LAIV-Q and any other live vaccine or a TB skin test.

Page 2 of 4

Please remove the following pages:

- 2019/20 Seasonal Influenza Vaccine Eligibility: page 1 dated September 2019
- Safety Issues Applicable to Influenza Vaccines: page 1 dated September 2019
- Intended Use of Influenza Vaccines: page 1 dated September 2019
- FLULAVAL® TETRA: pages 1 & 2 dated September 2019
- FLUZONE® QUADRIVALENT: pages 1 & 2 dated September 2019
- FLUVIRAL®: pages 1 & 2 dated September 2019
- AGRIFLU®: pages 1 & 2 dated September 2019

Please add the following pages:

- 2020/21 Seasonal Influenza Vaccine Eligibility: page 1 dated August 2020
- Safety Issues Applicable to Influenza Vaccines: page 1 dated August 2020
- Intended Use of Influenza Vaccines: page 1 dated August 2020
- FLUMIST QUADRIVALENT: pages 1-3 dated August 2020
- FLUZONE® QUADRIVALENT: pages 1 & 2 dated August 2020
- FLUVIRAL®: pages 1 & 2 dated August 2020
- AGRIFLU®: pages 1 & 2 dated August 2020
- FLUAD® : pages 1 & 2 dated August 2020
- FLUZONE® HIGH-DOSE: pages 1 & 2 dated August 2020

Please also remove the Title Page and Table of Contents for Part 4 – Biological Products dated July 2020, and replace with the enclosed updated Title Page and Table of Contents dated August 2020.

Supporting Documents

History of Immunization in BC

- Content of the School Immunization Programs section has been revised to include the end date for the routine grade 6 hepatitis B vaccine program. This vaccine continues to be offered in Grade 6 as a catch-up for those who are not up-to-date.
- Influenza Vaccine section has been updated to include the products used in the 2019/20 and 2020/21 influenza seasons.

Please remove the entire section and replace with the revised section dated August 2020.

Latex Content in Vaccines

- Act-HIB® was removed from the table “Vaccines Containing Latex” and is now listed as one of the products that does not contain latex. MENJUGATE® was also removed from the table as it is no longer marketed.
- The following products have been added to the list of products that do not contain latex: FLUZONE® HIGH-DOSE, KamRAB™, and SHINGRIX®.

Please remove page number: 1 dated May 2017
Please add page number: 1 dated August 2020

If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,



Monika Naus MD MHSc FRCPC FACPM
Medical Director
Communicable Diseases & Immunization Service
BC Centre for Disease Control

pc:

Provincial Health Officer
Dr. Bonnie Henry

Dr. Reka Gustafson
Vice President, Public Health &
Wellness, PHSA & Deputy Provincial
Health Officer

Deputy Provincial Health Officer
Dr. Martin Lavoie

BC Ministry of Health, Population &
Public Health Division:

Brian Sagar
Senior Director Communicable
Disease, Population and Public Health
Division

Bernard Achampong
Executive Director,
Public Health, Planning and Prevention,
Population and Public Health Division